About Type 2 Diabetes
Type 2 diabetes is a chronic condition, which arises due to either the inability of the body to produce enough insulin or insulin resistance, or both. Insulin is a peptide hormone produced by the Islets of Langerhans (pancreatic cells). It is produced in an immature form called preproinsulin, which is proteolytically cleaved to obtain proinsulin and then insulin. Type 2 diabetes nearly accounts for 90-95 percent of the total diabetic cases. Type 2 diabetes is usually diagnosed in middle-aged and older people; however, it can occur even during childhood. Type 2 diabetes was also known as adult-onset diabetes or non-insulin-dependent diabetes. Risk factors for type 2 diabetes include high blood pressure, advancing age, overweight, history of gestational diabetes, family history of diabetes, ethnicity, poor nutrition during pregnancy, unhealthy diet, physical inactivity, and IGT.
TechNavio's analysts forecast the Global Type 2 Diabetes Therapeutics market to grow at a CAGR of 7.15 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Type 2 Diabetes Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of following drugs:
• DPP-4 inhibitors
• Biguanides
• Insulins
• GLP-1 receptor agonists
• Thiazolidenediones
• Sulfonulureas
• SGLT-2 inhibitors
• a-Glucosidase inhibitors
• Others (amylinomimetics, bile acid sequestrants, and dopamine receptor agonists)
Further, the territories considered in the report include:
• Americas (US, Brazil, and Mexico)
• 5EU (France, Germany, Italy, Spain, and UK)
• APAC (China, Japan, India, Russia, and other APAC countries)
TechNavio's report, Global Type 2 Diabetes Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Type 2 Diabetes Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Novartis
• Novo Nordisk
Other Prominent Vendors
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly
• Merck
• Sanofi
Market Driver
• Increased Awareness on Type 2 Diabetes
• For a full, detailed list, view our report
Market Challenge
• Poor Diagnosis Rate
• For a full, detailed list, view our report
Market Trend
• Focus on Emerging Markets
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
07. WHO Diagnostic Criteria for Type 2 Diabetes
08. Treatment Algorithm for Type 2 Diabetes by IDF
09. Incidence and Prevalence
10. Five Forces Analysis
11. Market Segmentation by Drug Class
11.1.1 DPP-4 Inhibitors
11.1.2 Biguanides
11.1.3 Insulin
11.1.4 GLP-1 Receptor Agonists
11.1.5 Thiazolidinediones
11.1.6 Insulin Secretagogues
11.1.7 SGLT-2 Inhibitors
11.1.8 Alpha-glucosidase Inhibitors
11.1.9 Others
12. Key Leading Countries
12.1 US
12.2 Japan
12.3 China
13. Geographical Segmentation
13.1 Type 2 Diabetes Therapeutics Market in Americas
13.1.1 Market Segmentation by Country 2014
13.1.2 Type 2 Diabetes Therapeutics Market in US
13.1.3 Type 2 Diabetes Therapeutics Market in Latin America
13.2 Type 2 Diabetes Therapeutics Market in APAC Region
13.2.1 Market Segmentation by Country 2014
13.2.2 Type 2 Diabetes Therapeutics Market in China
13.2.3 Type 2 Diabetes Therapeutics Market in Japan
13.2.4 Type 2 Diabetes Therapeutics Market in 5EU
13.3 Type 2 Diabetes Therapeutics Market in BRIC Countries
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.2.1 AstraZeneca
21.2.2 Novartis
21.2.3 Novo Nordisk
21.3 Other Prominent Vendors
22. Key Vendor Analysis
22.1 AstraZeneca
22.1.1 Business Overview
22.1.2 Business Segmentation
22.1.3 Key Information
22.1.4 SWOT Analysis
23.2 Novartis
22.2.1 Business Overview
22.2.2 Business Segmentation
22.2.3 Key Information
22.2.4 SWOT Analysis
22.3 Novo Nordisk
22.3.1 Business Overview
22.3.2 Business Segmentation
22.3.3 Key Information
22.3.4 SWOT Analysis
23. Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Regulation of Blood Glucose Levels by Insulin and Glucagon
Exhibit 3: Major Complications Arising Because of Diabetes
Exhibit 4: Global Type 2 Diabetes Therapeutics Market 2014-2019 (US$ billion)
Exhibit 5: FDA Approved NMEs for Type 2 Diabetes 2011-2014
Exhibit 6: Conclusions of Time 2 Do More in Diabetes Survey
Exhibit 7: WHO Diagnostic Criteria for Type 2 Diabetes
Exhibit 8: Treatment Algorithm for Type 2 Diabetes by IDF
Exhibit 9: Advantages and Disadvantages of Using Metformin for Treatment of Type 2 Diabetes
Exhibit 10: Advantages and Disadvantages of Using Sulfonylureas and Alpha-glucosidase Inhibitors for Treatment of Type 2 Diabetes
Exhibit 11: Advantages and Disadvantages of Using Thiazolidinediones for Treatment of Type 2 Diabetes
Exhibit 12: Prevalence of Diabetes by IDF Region 2013
Exhibit 13: Prevalence of Diabetes 2013
Exhibit 14: Comparative Prevalence of Diabetes by IDF Region 2013 and 2035 (20-79 years)
Exhibit 15: Segmentation of Global Type 2 Diabetes Therapeutics Market by Drug Class
Exhibit 16: Segmentation of Global Type 2 Diabetes Therapeutics Market by Drug Class 2014
Exhibit 17: Insulin Secretagogues by Drug Class
Exhibit 18: Segmentation of Global Type 2 Diabetes Therapeutics Market by Geography 2014
Exhibit 19: Segmentation of Global Type 2 Diabetes Therapeutics Market by Geography 2019
Exhibit 20: Segmentation of Global Type 2 Diabetes Therapeutics Market by Geography 2014-2019 (US$ billion)
Exhibit 21: YoY Growth Rate of Global Type 2 Diabetes Therapeutics Market Segments by Geography 2014-2019
Exhibit 22: Segmentation of Global Type 2 Diabetes Therapeutics Market by Country/Region 2014
Exhibit 23: Type 2 Diabetes Therapeutics Market in Americas 2014-2019 (US$ billion)
Exhibit 24: Segmentation of Type 2 Diabetes Therapeutics Market in Americas by Country 2014
Exhibit 25: Type 2 Diabetes Therapeutics Market in US 2014-2019 (US$ billion)
Exhibit 26: Type 2 Diabetes Therapeutics Market in Latin America 2014-2019 (US$ billion)
Exhibit 27: Segmentation of Type 2 Diabetes Therapeutics Market in Latin America by Country 2014
Exhibit 28: Segmentation of Type 2 Diabetes Therapeutics Market in Latin America by Country 2019
Exhibit 29: Type 2 Diabetes Therapeutics Market in Mexico 2014-2019 (US$ billion)
Exhibit 30: Segmentation of Type 2 Diabetes Therapeutics Market in Latin America by Country 2014-2019 (US$ billion)
Exhibit 31: Type 2 Diabetes Therapeutics Market in Brazil 2014-2019 (US$ billion)
Exhibit 32: Type 2 Diabetes Therapeutics Market in APAC Region 2014-2019 (US$ billion)
Exhibit 33: Segmentation of Type 2 Diabetes Therapeutics Market in APAC Region by Country 2014
Exhibit 34: Type 2 Diabetes Therapeutics Market in China 2014-2019 (US$ billion)
Exhibit 35: Type 2 Diabetes Therapeutics Market in Japan 2014-2019 (US$ billion)
Exhibit 36: Type 2 Diabetes Therapeutics Market in 5EU 2014-2019 (US$ billion)
Exhibit 37: Segmentation of Type 2 Diabetes Therapeutics Market in BRIC Countries 2014
Exhibit 38: Blue Circle: Global Symbol for Diabetes
Exhibit 39: Prevalence of Diabetes by IDF Region 2013 and 2035
Exhibit 40: Prevalence of IGT by Age 2013 and 2035
Exhibit 41: Prevalence of Diabetes and Prevalence of Undiagnosed Diabetes by IDF Region 2013
Exhibit 42: Diabetes Rule of Halves
Exhibit 43: Revenue Share of Novo Nordisk’s Insulin Products 2013
Exhibit 44: Segmentation of NovoRapid/NovoLog by Geography 2013 (US$ million)
Exhibit 45: Segmentation of NovoRapid/NovoLog by Geography 2013
Exhibit 46: NovoRapid/NovoLog Market Size and Forecast 2013-2018 (US$ million)
Exhibit 47: Segmentation of Revenue from Novo Nordisk’s Insulin Products by Geography 2013
Exhibit 48: Segmentation of Revenue from Novo Nordisk’s Insulin Products by Geography 2013 (US$ million)
Exhibit 49: Segmentation of Victoza by Geography 2013 (US$ million)
Exhibit 50: Segmentation of Victoza by Geography 2013
Exhibit 51: Victoza Market Size and Forecast 2013-2018 (US$ million)
Exhibit 52: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 53: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 54: AstraZeneca plc: Sales by Geography 2013
Exhibit 55: Novartis AG: Business Segmentation
Exhibit 56: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 57: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 58: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 59: Business Segments of Novo Nordisk A/S 2013
Exhibit 60: Novo Nordisk A/S: Business Segmentation 2013
Exhibit 61: Novo Nordisk A/S: Revenue Comparison 2012 and 2013 (US$ million)
Exhibit 62: Novo Nordisk A/S: Sales by Geography 2013
